Celaya RM, Moreno NJ

Language: Spanish
References: 26
Page: 129-144
PDF size: 133.73 Kb.

ABSTRACT

During 1999, bacteriological analyses and in vitro antibiotic susceptibility determination were practiced to a population of 22,150 assisted patients at Hospital General de México. The methodology used was the semiautomatized MicroScan system applied to dried Gram negative and Gram positive MIC combo panels. Four steps were followed: a) the collection of the samples by the traditional procedures e.g. the culturette or a sterile preservative medium; b) the culture of the samples on a series of conventionally used selective media in order to isolate the bacteria in Petri dishes; c) the identification to species level of the isolated microorganisms, with a mean probability higher than 85% in almost every case; and d) the determination of the susceptibility of each species to twenty one antibiotics, using bacterial dispersion taken from the respective cultures. The antibiotics tested were: several b-lactamics as penicilina, monobactamic, meropenem, imipenem, and cephalosporines of 1st, 2nd, and 3th generation, aminoglucosides as amikacine, and gentamicine, quinolones as ofloxacine, and levofloxacine, and ampicilline/sulbactam. A total of 95 bacterial species were determined, the most frequently isolated were: E. coli, S. aureus, K. pneumoniae, S. marcescens, P. aeruginosa, E. cloacae, P. mirabilis, C. freundii, M. morganii, A. iwoffii, K. oxytoca, E. brevis, A. baumann/haemolyticus, E. aglommerans, and S. maltophilia,. These fifteen species were simultaneous and independently exposed to the mentioned antibiotics in aqueous solution and their higher annual percentage of susceptibility is reported, the species were meanly isolated from the following kind of the samples and incidence order: urine (946 isolated), wound secretion (620), pharyngeal exuded (289), blood (169), anal secretion (142), vaginal exuded (136), expectoration (135), fluids of the body (115), and abscess (63).

REFERENCES

1. Madigan MT, Martinko JM, Parker JB. Biología de los Microorganismos. Prentice Hall, cap. I, II, IV, XI y apéndice No. 3, España 1997.

2. Davis BD, Dubelcco R, Eisen HN, Ginsberg HS, Wood Jr. WB, MaCarty M. Tratado de Microbiología, Inmunología y Genética, parte 1, 2 y 4, Ed. Salvat, España 1978.

3. Health JR. Science. 1995;270:1315-1316.

4. Walker G. New Scientist 1995: 28-31.

5. De Miguel I, Ioulalen K, Bonnefous M, Peyrot M, Nguyen F, Cervilla M, Soulet N, Dirson R, Rieumajou V, Imbertie L, Solers C, Cazes S, Favre G, Samain D. Biochemica et Biophysica Act 1237, 49-58 1995.

6. John Bernard Henry. Diagnóstico y tratamiento clínico por el laboratorio. Editorial Ediciones Científicas y Técnicas S.A. Masson-Salvat, 9ª Edición, cap. 42 y 51, México 1997.

7. Stanier RY, Adelberg EA, Ingraham JL. Microbiología. Ediciones Repla S.A., cap. 1, 2, 3, 5, 6 y 7, México 1986.

8. Mensa J, Castell JM, Corachán M, Escofet MC, Martínez JA, Zamora L. Guía de terapéutica antimicrobiana. Editorial Salvat, cap. 1-6, España 1991.

9. Calderón JE. Aplicaciones clínicas antibióticos y quimioterapéuticos. Editor Ernesto Calderón Jaimes, secciones I-V, México 1997.

10. Rosenstein SE. Los Medicamentos y las pruebas de laboratorio (Diccionario de Especialidades Farmacéuticas), Ediciones PLM. Índice de sustancias y sección de productos, México 1993.

11. Wepierre J. Manual de farmacología general y molecular. Editorial Masson Universidad de Colima, cap. 1, 2, 3 y 4, México 1988.

12. Dade Behring MicroScan, Dried Gram Negative Procedural Manual. Ed. Dade Behring, p.1-8, USA 1999.

13. Dade Behring MicroScan, Dried Gram Positive Procedural Manual. Ed. Dade Behring, partl-1-10, part II-1-12 USA 1999.

14. MicroScan, Gram Positive and Negative Panels Color Interpretation Chart. Baxter Diagnostics Inc, USA 1991.

15. MicroScan, Rapid Chromogenic Panels Color Interpretation Chart. Baxter Diagnostics Inc, USA 1991.

16. Bristol Myers Squibb, Cefepime Maxipime Monografía de Producto: La Revolución en la evolución de las cefalosporinas. Ed. Bristol Myers Squibb, México 1998.

17. Kawaguchi H. Discovery, chemistry, and activity of amikacina. The Journal of infectious diseases, 134 Supplement, November 1976.

18. Linzenmeier G, Naumann P, Neussel H, Rosin H. In vitro susceptibility of clinically important bacteria to amikacin. Correlation of results of broth dilution and disk sensitivity test and effect to medium composition. The journal of infectious diseases, (134) Supplement, November 1976.

19. Sanders CC, Sanders WE Jr. Microbial resistance to newer generation b-lactam antibiotics: Clinical and laboratory implications. J Infect Dis 1985;151:399-406.

20. Freund JE, Simon GA. Estadística elemental, Prentice-Hall, p.27, 148, México 1998.

21. Bryant MC. Antibióticos y su control mediante el laboratorio. Editorial El Manual Moderno S. A., p.1-22, México DF. 1976.

22. Schaechter M, Medoff G, Einsenstein BI, Guerra H. Microbiología, mecanismos de las enfermedades infecciosas (Enfoque mediante resolución de problemas). Editorial Médica Panamericana. México 1998.

23. Especialidades Farmacéuticas-PLM. Diccionario de especialidades farmacéuticas. Editorial PLM SA de CV, México 1998.

24. Lennette EH. Microbiología clínica. Editorial Médica Panamericana. p.338, México 1982.

25. Koneman W, Allen SD, Dowell YR, Sommers HM. Diagnóstico microbiológico texto y atlas. Editorial Médica Panamericana. México 1991.

26. Power DA, McCuen PJ. Manual of BBL products and laboratory procedures. David A. Power Ed. Sixth Edition, p: 1-16, USA 1988.